AORT logo

Artivion Inc Com (AORT)

$18.27

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AORT

Market cap

$891389134

EPS

-0.35

P/E ratio

--

Price to sales

2.2

Dividend yield

--

Beta

1.301815

Price on AORT

Previous close

$18.47

Today's open

$18.19

Day's range

$18.13 - $18.68

52 week range

$18.12 - $48.25

Profile about AORT

CEO

J. Patrick Mackin

Employees

1800

Headquarters

Kennesaw, GA

Exchange

New York Stock Exchange

Shares outstanding

48789772

Issue type

Common Stock

AORT industries and sectors

Healthcare

Medical Equipment & Supplies

News on AORT

Artivion Q3 Earnings Call Highlights

Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.

news source

MarketBeat • Nov 7, 2026

news preview

Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Artivion Reports Third Quarter 2026 Financial Results

Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9% on a non-GAAP constant currency basis  Net loss for the third quarter of 2026 was $(7.9) million, or $(0.16) per fully diluted share, and non-GAAP net income was $3.8 million, or $0.08 per fully diluted share Adjusted EBITDA declined 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. "In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.

news source

PRNewsWire • Nov 5, 2026

news preview

Artivion (AORT) Lags Q3 Earnings Estimates

Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Artivion to Participate in Upcoming Investor Conferences

ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at the Lotte New York Palace Hotel.

news source

PRNewsWire • Oct 28, 2026

news preview

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results

ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

news source

PRNewsWire • Oct 22, 2026

news preview

Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update

Class A shares of the Alger Dynamic Opportunities Fund outperformed the S&P 500 Index during the second quarter of 2026. For the quarter, the portfolio's average long exposure was 88.77% and the average short exposure was -37.38%. Long positions Nebius Group, Astera Labs, Inc., and Western Digital Corporation were among the top contributors to performance.

news source

Seeking Alpha • Aug 9, 2026

news preview

Artivion Q2 Earnings Call Highlights

Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.

news source

MarketBeat • Aug 7, 2026

news preview

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 7, 2026

news preview

Artivion Reports Second Quarter 2026 Financial Results

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis  Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.

news source

PRNewsWire • Aug 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Artivion Inc Com

Open an M1 investment account to buy and sell Artivion Inc Com commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AORT on M1